Peptides and ALS: Amyotrophic Lateral Sclerosis Research
Written by NorthPeptide Research Team | Reviewed January 22, 2026
What Is ALS?
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease affecting motor neurons in the brain and spinal cord. As these neurons die, the muscles they control weaken and atrophy. Most people with ALS lose the ability to speak, swallow, and breathe over the course of 2–5 years from diagnosis. Roughly 90% of cases are sporadic with no clear genetic cause; about 10% are familial.
Currently approved ALS treatments — riluzole, edaravone, and AMX0035 — modestly slow progression in some patients. The field urgently needs compounds that can protect surviving motor neurons, reduce excitotoxicity, and support mitochondrial function, which is severely compromised in ALS.
BPC-157: Neuroprotection and Motor Neuron Research
BPC-157 has been studied in rodent models of motor neuron injury and neurotoxicity. Its proposed mechanisms relevant to ALS research include reduction of glutamate excitotoxicity (a key driver of motor neuron death in ALS), modulation of nitric oxide signaling, and upregulation of growth factor pathways. In several animal models of nerve damage, BPC-157 improved motor function recovery and reduced neuronal apoptosis markers. While no ALS-specific BPC-157 clinical trials exist, its broad neuroprotective profile has made it a compound of interest in preclinical neurodegeneration research.
SS-31: Mitochondrial Protection
SS-31 (Szeto-Schiller peptide 31, also known as Elamipretide) is a cell-penetrating tetrapeptide that targets the inner mitochondrial membrane. It stabilizes cardiolipin — a phospholipid critical for the electron transport chain — and reduces mitochondrial reactive oxygen species (ROS) production. Mitochondrial dysfunction is a well-documented feature of ALS pathology; motor neurons in ALS patients show fragmented mitochondria, impaired ATP production, and elevated oxidative stress. SS-31’s ability to restore mitochondrial membrane potential has been demonstrated in multiple neurodegenerative model systems, making it relevant to ALS research frameworks.
Key Mechanisms Being Studied
- Excitotoxicity reduction: Blocking excess glutamate-mediated motor neuron death
- Mitochondrial stabilization: Restoring ATP production and reducing oxidative damage
- Anti-apoptotic signaling: Reducing programmed motor neuron death
- Neuroinflammation modulation: Reducing astrocyte and microglial inflammatory activation
- Growth factor support: Upregulating BDNF, GDNF, and related neurotrophins
Research Limitations and Honest Assessment
ALS is notoriously difficult to model in animals — many compounds that work in rodent ALS models have failed in human trials. The genetic and sporadic subtypes of ALS differ substantially in their underlying mechanisms. No peptide discussed here has undergone ALS-specific human clinical trials. Researchers should treat these findings as hypothesis-generating preclinical data, not as evidence of efficacy in human disease.
Explore Research Peptides
Browse NorthPeptide’s full catalog of third-party tested research compounds.
Written by the NorthPeptide Research Team
References
| PMID | Authors | Year | Key Finding |
|---|---|---|---|
| 30185439 | Sikiric et al. | 2018 | BPC-157 neuroprotective effects in motor injury and neurotoxicity models |
| 23602876 | Szeto | 2014 | SS-31 targets mitochondrial cardiolipin and reduces oxidative stress in neurodegeneration |
| 29409898 | Mancuso et al. | 2018 | Mitochondrial dysfunction as central mechanism in ALS pathology |